Olema Pharmaceuticals (OLMA) Current Assets (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Current Assets data on file, last reported at $513.2 million in Q1 2026.

• On a quarterly basis, Current Assets rose 29.39% year-over-year to $513.2 million in Q1 2026; TTM through Mar 2026 was $513.2 million, a 29.39% increase from a year earlier, with the FY2025 full-year figure at $515.5 million, up 17.56% from the prior year.
• Current Assets for Q1 2026 stood at $513.2 million, roughly flat from $515.5 million in the prior quarter.
• Over the last five years, Current Assets for OLMA reached as high as $515.5 million in Q4 2025 and fell as low as $171.5 million in Q2 2023.
• Historically, Current Assets has averaged $302.0 million across 5 years, with a median of $266.5 million in 2023.
• Across the five-year window, Current Assets fell 29.91% in 2023 and surged 64.52% in 2024, its largest moves.
• Year by year, Current Assets stood at $208.9 million in 2022, then advanced by 27.58% to $266.5 million in 2023, then jumped by 64.52% to $438.5 million in 2024, then climbed by 17.56% to $515.5 million in 2025, then declined by 0.43% to $513.2 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $513.2 million in Q1 2026, $515.5 million in Q4 2025, and $334.3 million in Q3 2025.